ReShape Lifesciences Inc. RSLS
Set alert
At close · Aug 14
- YTD
- -99.12%
- 1 year
- -99.62%
- Open
- 3.06
- Prev close
- 3.92
- Mkt cap
- 3.04M
- Vol
- 13.59M
- Avg vol
- 113.58K
- EPS
- 77.26
- P/E
- 0.06
- Div yield
- 0.00%
More statistics
- Low
- 2.80
- High
- 4.65
- Forward P/E
- -11.83
- Beta
- 1.35
- Short ratio
- 0.22
- Inst. own
- 1.83%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.39
- 200-d avg
- 9.00
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 8, 2023Earnings: -59.3; estimate 0; surprise —%
- May 15, 2024Earnings: -5.23; estimate 0; surprise —%
- Jul 17, 2024Downgrade: Maxim Group · Buy → Hold
- Aug 14, 2024Earnings: -3.49; estimate 0; surprise —%
- Sep 23, 2024Split: 1 for 58
- Nov 14, 2024Earnings: -3.11; estimate 0; surprise —%
- May 9, 2025Split: 1 for 25
Signals (75)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Aug 13, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| RSI: Oversold | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 23, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 5, 2024 | 1 year ago |
| SMA: Bearish | Dec 4, 2024 | 1 year ago |
| SMA: Bullish | Dec 3, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 27, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 21, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 19, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 11, 2024 | 2 years ago |
| RSI: Oversold | Oct 3, 2024 | 2 years ago |
| RSI: Oversold | Oct 1, 2024 | 2 years ago |
| RSI: Oversold | Sep 25, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 19, 2024 | 2 years ago |
| RSI: Oversold | Sep 19, 2024 | 2 years ago |
Newest 20 of 75.
Key statistics
- Market cap
- 3.04M
- Enterprise value
- 1.82M
- Trailing P/E
- 0.06
- Forward P/E
- -11.83
- PEG ratio
- 0.00
- Price / sales
- 0.38
- Price / book
- 0.26
- EPS (TTM)
- 77.26
- Beta
- 1.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -112.11%
- Revenue (TTM)
- 8.05M
- Revenue growth
- -12.80%
- Free cash flow
- -5.52M
- Total cash
- 1.05M
- Total debt
- 216.00K
- Return on equity
- -184.59%
- Shares outstanding
- 712.68K
- Short % of float
- 5.39%
- 50-day average
- 5.39
- 200-day average
- 9.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -3.11 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -3.49 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -5.23 | — | — |
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | -59.30 | — | — |
| Aug 7, 2023 | Jun 1, 2023 | 0.00 | -62.79 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 17, 2024 | Maxim Group | down | Buy | Hold |
About ReShape Lifesciences Inc.
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- reshapelifesciences.com
News
- Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
- Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
- Vyome Announces New Board of Directors with Deep MIT and AI Ties
- ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
- 12 Health Care Stocks Moving In Friday's After-Market Session
- ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
- ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
- ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
Your note
Sign in to keep a note on RSLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| STANKOVICH THOMAS | Chief Financial Officer | Sale | May 30, 2024 | 22,777 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.09% | 665 | 2.83K | Sep 29, 2024 |
| Blackrock Inc. | 0.08% | 588 | 2.50K | Sep 29, 2024 |
| Cornerstone Planning Group LLC | 0.00% | 3 | 12 | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.00% | 1 | 4 | Sep 29, 2024 |
| Planned Solutions, Inc. | 0.00% | 1 | 4 | Sep 29, 2024 |
| CIBC Private Wealth Group, LLC | 0.00% | 1 | 4 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.34% | 2,418 | 10.30K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.18% | 1,288 | 5.49K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.12% | 860 | 3.66K | Sep 29, 2024 |